TP53 and B-cell non-Hodgkin lymphoma: While the therapeutic efficacy of Pol I inhibition in B-cell lymphomas has been linked to p53 activation [21, 25], we have demonstrated in earlier studies that the efficacy of CX-5461 in solid tumours is independent of p53 and is associated with cell cycle arrest, senescence and autophagy [32].